By Josh Beckerman
Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys.
The company reported preliminary 2024 net product revenue of $1.79 billion, exceeding full-year guidance by over $100 million. This was up about 56% from 2023. For 2025, it expects net product revenue of $2.9 billion to $3.1 billion.
Sarepta had preliminary cash, cash equivalents, restricted cash and investments of about $1.5 billion as of Dec. 31.
The company will report complete results in late February.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 13, 2025 13:00 ET (18:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.